首页|PD-1抑制剂联合化疗对比贝伐珠单抗联合化疗一线治疗非鳞非小细胞肺癌的研究

PD-1抑制剂联合化疗对比贝伐珠单抗联合化疗一线治疗非鳞非小细胞肺癌的研究

扫码查看
目的:比较细胞程序性死亡受体-1(programmed cell death protein-1,PD-1)抑制剂联合化疗与贝伐珠单抗联合化疗一线治疗晚期非鳞非小细胞肺癌(non-squamous non-small cell lung cancer,nsNSCLC)的疗效.方法:回顾性收集 2014年 11月至2024年 3月于河北医科大学第四医院接受一线治疗的晚期nsNSCLC患者 237例.根据治疗方案分为PD-1抑制剂联合化疗(IC组)119例和贝伐珠单抗联合化疗(BC组)118例.采用倾向得分匹配(propensity score matching,PSM)平衡协变量.研究主要终点为无进展生存期(progression-free survival,PFS),次要终点为客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)、总生存期(overall survival,OS).结果:237例患者经PSM后IC组和BC组各 87 例,IC组和 BC组的 ORR分别为 31.0%(27/87)和 43.7%(38/87)(P=0.085),DCR为 96.6%(84/87)和 95.4%(83/87)(P=1.000).中位PFS IC组为 9.3个月,BC组为 9.1个月,两组差异无统计学意义(P=0.053).OS两组差异无统计学意义(两组均未达到中位OS,P=0.116).结论:PD-1抑制剂联合化疗对比贝伐珠单抗联合化疗一线治疗晚期nsNSCLC近期疗效无差异.
PD-1 inhibitor combined with chemotherapy versus bevacizumab combined with chemotherapy as first-line treatments for advanced non-squamous non-small cell lung cancer:a retrospective study
Objective:To compare the efficacy of programmed death-1(PD-1)inhibitors combined with chemotherapy with that of bevaci-zumab combined with chemotherapy as first-line treatments for advanced non-squamous non-small cell lung cancer(nsNSCLC).Methods:Retrospective collection of 237 patients with advanced nsNSCLC who received first-line treatment at the Fourth Hospital of Hebei Medical University from November 2014 to March 2024.According to the treatment plan,119 cases were assigned into PD-1 inhibitor com-bined with chemotherapy(IC group)and 118 cases were assigned into bevacizumab combined with chemotherapy(BC group).Propensity score matching(PSM)was used to balance covariates.The primary endpoint was progression-free survival(PFS),and the secondary end-points were objective response rate(ORR),disease control rate(DCR),and overall survival(OS).Results:Among 237 patients with PSM,87 were assigned to the IC group and 87 to the BC group,with respective ORRs of 31.0%(27/87)and 43.7%(38/87)(P=0.085)and respective DCRs of 96.6%(84/87)and 95.4%(83/87)(P=1.000).No significant difference in the median PFS was observed between the two groups,with a PFS value of 9.3 months in the IC group and 9.1 months in the BC group(P=0.053).In addition,the two groups also showed no significant difference in OS(neither group reached the median OS;P=0.116).Conclusions:There was no significant difference in the short-term efficacy between chemotherapy combined with PD-1 inhibitor and that combined with bevacizumab as first-line treatments for advanced nsNSCLC.

PD-1 inhibitorbevacizumabnon-squamous non-small cell lung cancer(nsNSCLC)

郑飞、李曙光、黄芳、史健、刘义冰

展开 >

河北医科大学第四医院肿瘤内科(石家庄市 050011)

河北医科大学第四医院放疗科(石家庄市 050011)

PD-1抑制剂 贝伐珠单抗 非鳞非小细胞肺癌

河北省2024年度医学科学研究计划项目

20241327

2024

中国肿瘤临床
中国抗癌协会

中国肿瘤临床

CSTPCD北大核心
影响因子:1.32
ISSN:1000-8179
年,卷(期):2024.51(15)